# A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

> **NCT07287982** · PHASE2 · RECRUITING · sponsor: **argenx** · enrollment: 60 (estimated)

## Conditions studied

- Spinal Muscular Atrophy (SMA)

## Interventions

- **BIOLOGICAL:** ARGX-119 IV
- **OTHER:** Placebo IV

## Key facts

- **NCT ID:** NCT07287982
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-19
- **Primary completion:** 2029-05-28
- **Final completion:** 2029-05-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07287982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07287982, "A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07287982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*